Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Philippe Solal-Celigny"'
Autor:
Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Emmanuelle Tchernonog, Anna Schmitt, Roch Houot, Caroline Dartigeas, Jean Michel Pignon, Selim Corm, Anne Banos, Christiane Mounier, Jehan Dupuis, Margaret Macro, Joel Fleury, Fabrice Jardin, Clementine Sarkozy, Ghandi Damaj, Pierre Feugier, Luc Matthieu Fornecker, Cecile Chabrot, Veronique Dorvaux, Krimo Bouadallah, Sandy Amorin, Reda Garidi, Laurent Voillat, Bertrand Joly, Philippe Solal Celigny, Nadine Morineau, Marie Pierre Moles, Hacene Zerazhi, Jean Fontan, Yazid Arkam, Magda Alexis, Vincent Delwail, Jean Pierre Vilque, Loic Ysebaert, Steven Le Gouill, Mary B. Callanan, for the Lymphoma Study Association
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrol
Externí odkaz:
https://doaj.org/article/79f2a1ceb2cb45838a53d023cfec6ba8
Autor:
Rémy Gressin, Sylvie Caulet-Maugendre, Eric Deconinck, Olivier Tournilhac, Emmanuel Gyan, Marie Pierre Moles, Abderrazak El Yamani, Jerome Cornillon, Jean François Rossi, Steven Le Gouill, Gérard Lepeu, Ghandi Damaj, Philippe Solal Celigny, Hervé Maisonneuve, Bernadette Corront, Jean Pierre Vilque, Philippe Casassus, Thierry Lamy, Marc Colonna, Philippe Colombat
Publikováno v:
Haematologica, Vol 95, Iss 8 (2010)
Background There is currently no international consensus for first-line treatment (prior to autologous stem cell transplantation) in mantle cell lymphoma patients. Here, we investigated the efficacy and tolerance of VAD associated with chlorambucil (
Externí odkaz:
https://doaj.org/article/35f5010c4707408ebdce6a9bdaab4625
Autor:
Loic Ysebaert, Anne Banos, Vincent Delwail, Roch Houot, Nicolas Daguindau, Reda Garidi, Margaret Macro, Ghandi Damaj, Bertrand Joly, Jean Pierre Vilque, Sylvain Carras, Mary Callanan, Fabrice Jardin, Marie Pierre Moles, Magda Alexis, Steven Le Gouill, Emmanuelle Tchernonog, Laurent Voillat, Hacene Zerazhi, Christiane Mounier, J. Fleury, Sandy Amorin, Anne Moreau, Jean Michel Pignon, Adrian Tempescul, Véronique Dorvaux, Yazid Arkam, Luc Fornecker, Caroline Dartigeas, Cecile Chabrot, Philippe Solal Celigny, Pierre Feugier, Remy Gressin, Anna Schmitt, Jean Fontan, Clémentine Sarkozy, Nadine Morineau, Jehan Dupuis, Selim Corm, Krimo Bouadallah
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2018, 104 (1), pp.138-146. ⟨10.3324/haematol.2018.191429⟩
Haematologica, Ferrata Storti Foundation, 2018, 104 (1), pp.138-146. ⟨10.3324/haematol.2018.191429⟩
International audience; We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95cbd06f520ccbc6898f00caf6e8a39
https://hal.archives-ouvertes.fr/hal-02265274
https://hal.archives-ouvertes.fr/hal-02265274
Autor:
Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary
Autor:
Guy Laurent, Patricia Franchi-Rezgui, Olivier Fitoussi, Corinne Haioun, Philippe Solal-Celigny, Marc Maynadié, Pierre Feugier, Ghandi Damaj, Pauline Brice, Gilles Salles, Maya Hacini, Pierre Leconte, Etienne Suc, Fatima Lazreg, D Pau, Frédéric Boissard
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2018, pp.1-4. 〈10.1080/10428194.2018.1434878〉
Leukemia & lymphoma, Taylor & Francis, 2018, pp.1-4. 〈10.1080/10428194.2018.1434878〉
Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma (NHL) subtype, accounting for approximately 20% of all NHLs [1]. This indolent and incurable disease usually displays a low...
Publikováno v:
British Journal of Haematology
British Journal of Haematology, Wiley, 2018, 180 (2), pp.217-223. ⟨10.1111/bjh.15023⟩
British Journal of Haematology, 2018, 180 (2), pp.217-223. ⟨10.1111/bjh.15023⟩
British Journal of Haematology, Wiley, 2018, 180 (2), pp.217-223. ⟨10.1111/bjh.15023⟩
British Journal of Haematology, 2018, 180 (2), pp.217-223. ⟨10.1111/bjh.15023⟩
Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory/relapsed follicular lymphoma patients, this study aimed to describe the real-life management of patients with refractory follicular lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82fe1b5230746e75fea372f61bc851fd
https://hal-normandie-univ.archives-ouvertes.fr/hal-02194318
https://hal-normandie-univ.archives-ouvertes.fr/hal-02194318
Autor:
Eric Emmanuel, Cedrik Lafont, Elena Pavluc, Fabrice Denis, Philippe Solal-Celigny, Olivier Dupuis, Loïc Campion, Laurence Juhel-Voog, Yohan Pointreau, Eric Voog, Hugues Bourgeois, Pauline du Rusquec, Julien Domont, G. Ganem, Sophie Roche, Katell Le Du, Marie Zinger
Publikováno v:
Supportive Care in Cancer
Supportive Care in Cancer, Springer Verlag (Germany), 2018, 26 (1), pp.81-89. ⟨10.1007/s00520-017-3816-3⟩
Supportive Care in Cancer, Springer Verlag (Germany), 2018, 26 (1), pp.81-89. 〈10.1007/s00520-017-3816-3〉
Supportive Care in Cancer, 2018, 26 (1), pp.81-89. ⟨10.1007/s00520-017-3816-3⟩
Supportive Care in Cancer, Springer Verlag (Germany), 2018, 26 (1), pp.81-89. ⟨10.1007/s00520-017-3816-3⟩
Supportive Care in Cancer, Springer Verlag (Germany), 2018, 26 (1), pp.81-89. 〈10.1007/s00520-017-3816-3〉
Supportive Care in Cancer, 2018, 26 (1), pp.81-89. ⟨10.1007/s00520-017-3816-3⟩
International audience; PURPOSE: Totally implantable venous access ports (TIVAP) have been widely used for many years in the management of patients suffering from cancer. The implantation and long-term use of TIVAPs are associated with mechanical, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a021eb96c41e6f4fe2f1bca4d0b717f
https://www.hal.inserm.fr/inserm-01808818
https://www.hal.inserm.fr/inserm-01808818
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Olivier Molinier, Jaafar Bennouna, N. Pourel, Hugues Bourgeois, Philippe Solal-Celigny, Fabrice Denis, Claude El Khouri, Anne-Lise Septans, P. Trémolières, Alexandre Charron, Sébastien Landry, Hélène Senellart, Yoann Pointreau, T. Lizée, Claire Lethrosne, Christophe Letellier, Magali Balavoine, Thierry Urban, Julien Domont
Publikováno v:
JNCI: Journal of the National Cancer Institute
JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2017, 109 (9), pp.djx029. ⟨10.1093/jnci/djx029⟩
JNCI: Journal of the National Cancer Institute, Oxford University Press (OUP), 2017, 109 (9), pp.djx029. ⟨10.1093/jnci/djx029⟩
WOS:000410799200009; International audience; Background: The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes. It remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695ad47311e3d29d3ae9bdf1ba2bb1bd
https://hal.archives-ouvertes.fr/hal-01611175
https://hal.archives-ouvertes.fr/hal-01611175
Autor:
Noppadol Siritanaratkul, Martin Barrett, Andrew Davies, David MacDonald, Artem Zharkov, Mark Dixon, Philippe Solal-Celigny, Santiago Mercadal, Francesco Merli, Biljana Mihaljevic, Michael Brewster, Magali Genevray, Claude Berge, Axel Boehnke
Publikováno v:
The Lancet. Haematology. 4(6)
Summary Background Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5–6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care.